Kestra Medical Technologies, Ltd. (KMTS) stock
KMTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends April 30
$28.27+0.30 (+1.07%)
Close on Nov 17, 2026Market cap $1.68BP/E –Yield –
Kestra Medical Technologies r&d expenses
Research and development expenses are spending on new products and technology.
Kestra Medical Technologies's R&D Expenses for the twelve months ending Jul 31, 2026 was $22.28M, up 37.1% year over year. For fiscal 2026 it was $19.48M, up 24.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $19.48M | +24.5% |
| FY2025 | Apr 30, 2025 | $15.65M | +1.0% |
| FY2024 | Apr 30, 2024 | $15.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $6.80M | +69.9% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $5.63M | +4.6% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $4.97M | +48.3% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $4.88M | +39.0% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $4.00M | +17.5% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $5.39M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $3.35M | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $3.51M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $3.40M | – |
See a number that looks wrong?